問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

柯文謙Ko, Wen-Chien
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

柯文謙

List

17Cases

2007-11-01 - 2008-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-05-01 - 2024-04-29

Phase II

Completed
A Phase Ⅱ,Double-blind,Randomized,Controlled Study to Evaluate the Safety and Efficacy of Silmitasertib(CX-4945) in Hospitalized Adults with COVID-19

  • Condition/Disease

    Community-acquired Pneumonia 、SARS-CoV-2 -Associated Pneumonia 、Influenza With Pneumonia

  • Test Drug

    CX-4945

Participate Sites
1Sites

Recruiting1Sites

2009-11-01 - 2010-01-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-01-01 - 2010-10-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2021-03-01 - 2028-03-31

Phase III

Completed
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants

  • Condition/Disease

    HIV-1 Infection

  • Test Drug

    MK-8591A [Doravirine (MK-1439) + Islatravir (MK-8591)]BiktarvyR

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2005-12-01 - 2007-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-01-01 - 2023-12-31

Phase III

A phase III, randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-1 infected adults

  • Condition/Disease

    HIV

  • Test Drug

    UB-421

Participate Sites
12Sites

Not yet recruiting10Sites

Recruiting1Sites

2008-12-08 - 2009-12-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-10-01 - 2021-12-31

Phase II

Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

  • Condition/Disease

    Dengue

  • Test Drug

    tetravalent live attenuated dengue vaccine admixture TV005

Participate Sites
4Sites

Not yet recruiting2Sites

Terminated1Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2020-12-26 - 2022-06-30

Phase II

A Phase II, Prospective, Double-blinded, Multi-Centered, Multi-Regional Study to Evaluate the Safety, Tolerability and Immunogenicity of the SARS-CoV-2 vaccine candidate MVC-COV1901

  • Condition/Disease

    COVID-19

  • Test Drug

    MVC-COV1901 vaccine

Participate Sites
11Sites

Not yet recruiting7Sites

Recruiting1Sites

Terminated3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB